- Home
- MINE vs CRBP Comparison
MINE vs CRBP Comparison
Compare MINE & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MINE | CRBP |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.9M | 190.3M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MINE | CRBP |
|---|---|---|
| Price | $2.29 | $3.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $33.22 |
| AVG Volume (30 Days) | 87.1K | ★ 1.1M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $131.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $2.16 | $2.81 |
| 52 Week High | $4.45 | $12.88 |
Technical Indicators
Market Signals| Indicator | MINE | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 35.45 |
| Support Level | $2.24 | $2.81 |
| Resistance Level | $2.59 | $8.13 |
| Average True Range (ATR) | 0.14 | 0.43 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 25.64 | 43.14 |
Price Performance
Historical ComparisonAbout MINE Mayfair Gold Corp. Common Shares
Mayfair Gold Corp is a mineral exploration company that is engaged in the acquisition and exploration of mineral properties. It has one material mineral property, the Fenn-Gib Gold Property, located in the Guibord, Munro, Michaud, and McCool Townships in northeast Ontario, which is in the exploration stage.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.